M. Imran Qadir1, M. Saleem1, Syed Haroon Khalid2, Salman Akbar Malik3, Asif Massud1, Mohsin Ali1, Sajid Asghar1 and M. Sajid Hamid Akash1
1. College of Pharmacy, GC University, Faisalabad, Pakistan 2. School of Pharmaceutical Sciences, University Sains Malaysia, Pulau Pinang, Malaysia 3. Department of Biochemistry, Quaid-i-Azam University, Islamabad, Pakistan
Keywords: Cancers, Leukemia, Plasma lipid profile, Triglycerides, Cholesterol, LDL-Cholesterol and HDL-Cholesterol

Neoplastic disease indicates a disease of new growth. Neoplasms or tumors may be divided into two categories; benign tumors and malignant tumors. Benign tumors are relatively innocent and remain localized. Malignant tumors are also called cancers and are distinguished from benign tumors by the properties of invasiveness and metastasis. Cancer of the leukocytes and their precursors is known as leukemia. Triglycerides, cholesterol, LDL-cholesterol and HDL-cholesterol constitute plasma lipid profile. Objective of the present study was to investigate relationship of plasma lipid profile (Triglycerides, Cholesterol, LDL-Cholesterol and HDL-Cholesterol) with leukemia. 180 subjects were included in the study. The subjects comprised of two groups; first as Controls (90 in number) and the second as Patients of Leukemia (also 90 in number). Fasting blood samples were collected for estimation of plasma lipid levels. Comparison between mean values of plasma lipid profile of control subjects and leukemia patients indicated that there was moderate decrease in all plasma levels of leukemia patients: triglycerides (31.29%, P < 0.01), cholesterol (27.15%, P < 0.01), LDL-cholesterol (23.28%, P < 0.01) and HDL-cholesterol (24.70%, P<0.05). As there is a change in plasma lipid profile of leukemia patients, the plasma lipid profile may be used as adjuvant for identification of the disease along with the standard diagnostics tools.

Article Information

Identifiers and Pagination:
First Page:45
Last Page:50
Publisher Id:JAppPharm (2011 ). 3. 45-50
Article History:
Received:September 11, 2010
Accepted:January 7, 2011
Collection year:2010
First Published:January 11, 2011

© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany


Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights
Abbreviation: J App Pharm
Frequency: Annual 
Current Volume: 9 (2017)
Next scheduled volume: December, 2018 (Volume 10)
Back volumes: 1-9
Starting year: 2009
Nature: Online 
Submission: Online  
Language: English

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885